Should We Alter the Human Genome? Let Democracy Decide
By Krishanu Saha, J. Benjamin Hurlbut & Sheila Jasanoff,
Scientific American
| 01. 15. 2020
We need greater scientific and moral clarity on germ line editing.
In November 2018, a Chinese scientist, He Jiankui, caused an international uproar by announcing the birth of two babies whose DNA he had edited using a tool called CRISPR-Cas9. Human germline genome editing—that is, making precise changes in human DNA that can be passed down through generations—has been seen for decades as a line that should not be crossed. This past December, He was sentenced to three years in prison for carrying out an “illegal medical practice.”
Yet, as the Chinese experiment shows, the state of technology no longer bars those who are willing to cross it. He’s experiment was a profound scientific and ethical misstep. Not only did he do it before adequate preparatory studies had been undertaken, but he acted unilaterally, deploying a technology with the potential to affect deeply held beliefs about human life all around the planet. His experiment set a dangerous example for other overly eager scientists. In mid-2019, a Russian scientist proposed a similar experiment.
We cannot blame lax oversight on China alone. The scientist who carried out the controversial first experiment in China...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
